Pivotal study designs revealed
Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.
Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.
Poor efficacy clouds prospects for the company's "improved" Yervoy.
Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
Gilead links up with Tubulis, while GSK taps BioNTech’s partner DualityBio.
Party season approaches; but first, conferences.